PFE Pfizer Inc

$25.05

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/18/2025

About Pfizer Inc

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Website: https://www.pfizer.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
78003
Address
235 E 42ND ST, NEW YORK, NY, US
Valuation
Market Cap
$125.57B
P/E Ratio
15.70
PEG Ratio
0.53
Price to Book
1.42
Performance
EPS
$1.41
Dividend Yield
7.77%
Profit Margin
12.60%
ROE
9.06%
Technicals
50D MA
$25.11
200D MA
$27.20
52W High
$30.55
52W Low
$20.91
Fundamentals
Shares Outstanding
6B
Target Price
$30.16
Beta
0.60

PFE EPS Estimates vs Actual

Estimated
Actual

PFE News & Sentiment

Aug 18, 2025 • GlobeNewswire NEUTRAL
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis ( FAP )
August ...
Aug 18, 2025 • Motley Fool NEUTRAL
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year
These three businesses have been raising their payouts for at least 16 consecutive years.
Aug 18, 2025 • Benzinga NEUTRAL
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain ( France ) , August 18, 2025 - Valneva SE VALNVLA, a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years ...
Aug 18, 2025 • GlobeNewswire NEUTRAL
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain ( France ) , August 18, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus ...
Aug 17, 2025 • GlobeNewswire NEUTRAL
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma ( NASDAQ: AAPG. HKEX: 6855 ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet ...
Aug 16, 2025 • Motley Fool SOMEWHAT-BULLISH
2 Top Dividend Stocks to Buy on the Dip
These blue chip healthcare stocks could still deliver strong long-term returns.
Sentiment Snapshot

Average Sentiment Score:

0.159
50 articles with scored sentiment

Overall Sentiment:

Bullish

PFE Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.25 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.67
  • Whisper:
  • Surprise %: 36.5%
Feb 04, 2025
Dec 31, 2024 (Pre market)
0.16 Surprise
  • Reported EPS: $0.63
  • Estimate: $0.47
  • Whisper:
  • Surprise %: 34.0%
Oct 29, 2024
Sep 30, 2024 (Pre market)
0.44 Surprise
  • Reported EPS: $1.06
  • Estimate: $0.62
  • Whisper:
  • Surprise %: 71.0%
Jul 30, 2024
Jun 30, 2024 (Pre market)
0.14 Surprise
  • Reported EPS: $0.60
  • Estimate: $0.46
  • Whisper:
  • Surprise %: 30.4%
May 01, 2024
Mar 31, 2024 (Pre market)
0.3 Surprise
  • Reported EPS: $0.82
  • Estimate: $0.52
  • Whisper:
  • Surprise %: 57.7%
Jan 30, 2024
Dec 31, 2023 (Pre market)
0.32 Surprise
  • Reported EPS: $0.10
  • Estimate: $-0.22
  • Whisper:
  • Surprise %: 145.4%
Oct 31, 2023
Sep 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.17
  • Estimate: $-0.34
  • Whisper:
  • Surprise %: 50.0%
Aug 01, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $0.67
  • Estimate: $0.57
  • Whisper:
  • Surprise %: 17.5%
May 02, 2023
Mar 31, 2023 (Pre market)
0.25 Surprise
  • Reported EPS: $1.23
  • Estimate: $0.98
  • Whisper:
  • Surprise %: 25.5%

Financials